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*BRAFV600* mutations (*BRAF^V600mut^*) are detected in about 50% of lesions from patients with metastatic melanoma. In the last few years, clinical treatment of melanoma has benefited from the approval of personalised therapies targeting *BRAFV600*. These innovative therapies still require molecular biomarkers predicting response duration. Circulating tumour DNA (ctDNA) appears to be a promising tool thanks to its ability to capture tumour heterogeneity. Detection of *BRAF^V600mut^* in ctDNA (ct*BRAF^V600mut^*) could be a hopeful tool to monitor and predict clinical response in melanoma treated with BRAF/MEK inhibitors.

Low baseline levels (pretreatment initiation) of ct*BRAF^V600mut^* have been found to be significantly associated with longer progression-free survival (PFS) and variation in ct*BRAF^V600mut^* levels during treatment was associated with the clinical course.[@R1] Similarly, overall survival (OS) was significantly associated with *BRAF^V600mut^* status in ctDNA prior to any targeted therapy.[@R3] Furthermore, a significantly higher PFS was found for patients in whom ct*BRAF^V600mut^* became undetectable at some time point after initiation of targeted therapy.[@R4]

From 2012 to 2014, 85 patients from the onco-dermatology department of the Saint-Louis Hospital (Paris, France) presenting unresectable stage III (n=12) or stage IV (n=73) melanoma with *BRAF^V600E^* mutated lesions at targeted therapy initiation (BRAF inhibitors, vemurafenib or dabrafenib) were included in this retrospective study after signed informed consent. The cohort included 52 (62%) patients presenting a stage IV m1c melanoma, and 23 (27%) had brain metastasis. Clinical response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) V.1.1 criteria. Detection of ct*BRAF^V600mut^* was monitored at baseline and during therapy using the highly sensitive E-ice-COLD-PCR method (0.1% sensitivity threshold).[@R5] The aim was to study the potential of *BRAF^V600mut^* detection in ctDNA as a predictor of tumour escape at baseline and at early intervals after therapy initiation.

Consistent with previous studies,[@R1] 68% of patients (58/85) presented a ct*BRAF^V600mut^* detection at first visit. Our study focused on the 53 patients with a blood sample within the first 3 months after therapy initiation and categorized them into two groups according to their ct*BRAF^V600mut^* status at this postinitiation visit, regardless of their ct*BRAF^V600mut^* status prior to treatment. Univariate analysis highlighted a significant difference (p=0.036, log-rank test) for PFS (time between therapy initiation and disease progression) with a median of 5.3 months and 2.8 months for wild-type patients and *BRAF^V600mut^* in ctDNA patients, respectively ([figure 1](#F1){ref-type="fig"}). No significant association was found for OS (time between therapy initiation and death). Cox multivariate analysis allowed the estimation of the risk for ct*BRAF^V600mut^* positive status associated with the PFS adjusted on patient's sex and melanoma stage: HR (CI 95%)=2.81 (1.43 to 5.54).
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Awaiting confirmation on larger cohorts, our results demonstrate that early detection of ct*BRAF^V600mut^* is associated with PFS, which represents a promising predictive tool in clinical practice. As the pretreatment ct*BRAF^V600mut^* status and the longitudinal monitoring are rarely performed in daily clinical practice, our results show the clinical value of *BRAF^V600mut^* detection in ctDNA early after initiation of targeted therapy (\<3 months). Such tool may allow the anticipation of clinical response and assessment of secondary resistance, hence facilitating earlier management of melanoma patients treated with targeted therapies.
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